What is aptLNP?
Current lipid nanoparticles distribute mainly to the liver, limiting their potential. Our aptLNP platform expands the use cases for LNPs by adding a proprietary targeting layer to guide them to specific, extra-hepatic tissues and cell types.
Using a targeting layer that can be added in plug-and-play fashion to existing LNP formulations and programmed against virtually any cellular receptor, we are developing a panel of aptLNPs to accurately target specific cell types such as cancer cells and immune cells.
Delivering nucleic acids, by nucleic acids
Aptamers are folded oligonucleotides that bind specifically to protein targets. aptLNP uses cell receptor-specific aptamers as programmable targeting ligands to tune up affinity and specificity while tuning down immunogenicity.
Because on-target vs. off-target cells are often defined by more than one receptor or by “fuzzy” expression level differences, aptLNP can also target the combination of multiple cell surface receptors – the surfaceome of cells – to enable the most accurate delivery for challenging indications.
Enabling in vivo Cell Therapy
Existing ex vivo cell therapies such as therapeutic CAR-T require complex and time-consuming manufacturing for each patient. We are developing a scalable aptLNP platform to enable in vivo generation of CAR-T cells, making this powerful therapy simpler for developers to produce and safer for patients to use.
No permanent CAR integration
In vivo off-the-shelf drug
Repeatable, non viral dosing
No preconditioning required
We have developed tools to help LNP drug developers design and optimize their drug’s in vivo distribution profile.